Michael A. Rogawski
University of California, Davis
H-index: 94
North America-United States
Top articles of Michael A. Rogawski
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Interim Long-term Safety and Efficacy of XEN1101, a Potent, Selective Potassium Channel Opener: Update from an Ongoing Open-label Extension of a Phase 2b Study (X-TOLE) in … | Jacqueline French Roger Porter Emilio Perucca Martin Brodie Michael Rogawski | 2024/4/14 | |
Efficacy of EP102 (Oral Fospropofol) for the Acute Treatment of Migraine in an Open-label Proof-of-concept Trial: Effect of Time to Treatment (P6-12.009) | Allen H Heller Kathryn Nelson Emily Michael Rogawski | 2024/4/14 | |
Crossover Study Evaluating the Effect of Seizures on the Absorption of Diazepam from a Buccal Film Formulation in Children with Epilepsy (P9-1.006) | Gary Slatko Stephen Wargacki Michael Rogawski | 2024/4/14 | |
Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids | 2023/4/13 | ||
Propofol prodrug methods and compositions | 2023/3/16 | ||
Efficacy and safety of XEN1101, a novel potassium channel opener, in adults with focal epilepsy: a phase 2b randomized clinical trial | JAMA neurology | Jacqueline A French Roger J Porter Emilio Perucca Martin J Brodie Michael A Rogawski | 2023/11/1 |
Fospropofol methods and compositions | 2023/9/7 | ||
A randomized, open‐label, two‐treatment crossover study to evaluate the effect of food on the pharmacokinetics of diazepam nasal spray in healthy adults | Epilepsia | Michael A Rogawski Gary Slatko | 2023/2 |
Tolerability and pharmacokinetics of intravenous allopregnanolone with and without midazolam pretreatment in two healthy dogs | Epilepsia Open | Donald A Bruun Betty Ma Yi‐Je Chen Chun‐Yi Wu Monica Aleman | 2023/6 |
XEN1101, a Novel Potassium Channel Modulator: Interim Data From an Ongoing, Long-Term, Open-Label Extension of a Phase 2b study (X-TOLE) in Adults with Focal Epilepsy (S44. 008) | Jacqueline French Roger Porter Emilio Perucca Martin Brodie Michael Rogawski | 2023/4/25 | |
Allopregnanolone as a Regenerative Therapeutic for Early Alzheimer’s Disease: Phase 1b/2a Clinical Trial Outcomes (P6-3.001) | Gerson Hernandez Claudia Lopez Wendy Mack Sonia Pawluczyk Dawn Matthews | 2022/5/3 | |
Intravenous and intramuscular allopregnanolone for early treatment of status epilepticus: pharmacokinetics, pharmacodynamics, and safety in dogs | Journal of Pharmacology and Experimental Therapeutics | Irene Vuu Edward E Patterson Chun-Yi Wu Dorota Zolkowska Ilo E Leppik | 2022/2/1 |
Phase 2b Efficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Onset Seizures (X-TOLE) | Jacqueline French Roger Porter Emilio Perucca Martin Brodie Michael A Rogawski | 2022/9/1 | |
Allopregnanolone compositions and uses thereof | 2022/6/30 | ||
Anticonvulsant activity of steroids | 2021/4/8 | ||
Antiseizure drugs | Basic & Clinical Pharmacology. McGrawHill, Duluth, MN | Michael A Rogawski | 2021 |
Intranasal allopregnanolone confers rapid seizure protection: Evidence for direct nose-to-brain delivery | Neurotherapeutics | Dorota Zolkowska Chun-Yi Wu Michael A Rogawski | 2021/1/1 |
Strain differences in the extent of brain injury in mice after tetramethylenedisulfotetramine-induced status epilepticus | Neurotoxicology | Jonas J Calsbeek Eduardo A González Casey A Boosalis Dorota Zolkowska Donald A Bruun | 2021/12/1 |
Cortical excitability threshold can be increased by the AMPA blocker Perampanel in amyotrophic lateral sclerosis | Muscle & Nerve | Björn Oskarsson Elizabeth A Mauricio Jaimin S Shah Zhuo Li Michael A Rogawski | 2021/8 |
Perampanel, a potent AMPA receptor antagonist, protects against tetramethylenedisulfotetramine-induced seizures and lethality in mice: comparison with diazepam | Archives of Toxicology. Archiv für Toxikologie | Zolkowska Dorota Dhir Ashish Michael A Rogawski | 2021/7/1 |
Co-Authors
